ECSP089011A - TUMORS TREATMENT IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE GROWTH FACTOR RECEIVER - Google Patents

TUMORS TREATMENT IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE GROWTH FACTOR RECEIVER

Info

Publication number
ECSP089011A
ECSP089011A EC2008009011A ECSP089011A ECSP089011A EC SP089011 A ECSP089011 A EC SP089011A EC 2008009011 A EC2008009011 A EC 2008009011A EC SP089011 A ECSP089011 A EC SP089011A EC SP089011 A ECSP089011 A EC SP089011A
Authority
EC
Ecuador
Prior art keywords
antagonists
growth factor
pediatric patients
tumors
tumors treatment
Prior art date
Application number
EC2008009011A
Other languages
Spanish (es)
Inventor
Eric Rowinsky
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of ECSP089011A publication Critical patent/ECSP089011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los métodos de terapia de combinación para tratar tumores pediátricos mediante la administración de un antagonista del EGFR y un agente quimioterapéutico. Los métodos incluyen tratar tumores pediátricos refractarios.Combination therapy methods to treat pediatric tumors by administering an EGFR antagonist and a chemotherapeutic agent. The methods include treating pediatric refractory tumors.

EC2008009011A 2006-07-27 2008-12-24 TUMORS TREATMENT IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE GROWTH FACTOR RECEIVER ECSP089011A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27

Publications (1)

Publication Number Publication Date
ECSP089011A true ECSP089011A (en) 2009-01-30

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008009011A ECSP089011A (en) 2006-07-27 2008-12-24 TUMORS TREATMENT IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE GROWTH FACTOR RECEIVER

Country Status (15)

Country Link
EP (1) EP2043688A4 (en)
JP (1) JP2009544736A (en)
KR (1) KR20090033841A (en)
CN (1) CN101484186A (en)
AU (1) AU2007279261A1 (en)
BR (1) BRPI0712368A2 (en)
CA (1) CA2654911A1 (en)
CR (1) CR10486A (en)
EA (1) EA200870603A1 (en)
EC (1) ECSP089011A (en)
MX (1) MX2008016187A (en)
NO (1) NO20085182L (en)
TN (1) TNSN08512A1 (en)
WO (1) WO2008014386A2 (en)
ZA (1) ZA200810600B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210148228A (en) 2019-03-27 2021-12-07 내셔날 리서치 카운실 오브 캐나다 Anti-EGFRvIII antibodies and antigen-binding fragments thereof

Also Published As

Publication number Publication date
JP2009544736A (en) 2009-12-17
BRPI0712368A2 (en) 2012-06-05
CA2654911A1 (en) 2008-01-30
MX2008016187A (en) 2009-01-20
NO20085182L (en) 2009-04-24
KR20090033841A (en) 2009-04-06
AU2007279261A1 (en) 2008-01-31
WO2008014386A2 (en) 2008-01-31
WO2008014386A3 (en) 2008-07-03
EP2043688A2 (en) 2009-04-08
TNSN08512A1 (en) 2010-04-14
EP2043688A4 (en) 2009-11-11
CN101484186A (en) 2009-07-15
EA200870603A1 (en) 2009-06-30
ZA200810600B (en) 2009-11-25
CR10486A (en) 2009-02-23

Similar Documents

Publication Publication Date Title
PH12015502155A1 (en) Myostatin antagonism in human subjects
MX381475B (en) COMBINATION THERAPY USING LIPOSOMAL IRINOTECAN AND A POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR FOR THE TREATMENT OF CANCER.
NZ587706A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0908635B8 (en) compound and/or a pharmaceutically acceptable salt thereof and pharmaceutical composition
EA200970953A1 (en) SPECIFIC INHIBITORS PDGFRβ
UA108618C2 (en) APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
SG10201902664RA (en) Combination therapy for treating cancer
MX2009006779A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors.
RU2013148721A (en) COMBINATIONS OF COMPOUNDS INHIBITING ACT AND VEMURAFENIBA AND WAYS OF THEIR APPLICATION
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
CL2008001932A1 (en) Compounds derived from 6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-b] pyridazine, cq1epsilon and / or ck1delta inhibitors; preparation procedure; pharmaceutical composition comprising them; and use in the treatment of sleep disorders, circadian rhythm disorder, cancer, and Alzheimer's disease.
PH12013500618A1 (en) Therapeutic use of a tlr agonist and combination therapy
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
EA201201464A1 (en) NEW COMBINED THERAPY FOR THE TREATMENT OF CANCER AND FIBROUS DISEASES
IN2014DN11099A (en)
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
NZ598145A (en) Folate-targeted diagnostics and treatment
MY199382A (en) Methods of treating circadian rhythm sleep disorders
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
EA201101651A1 (en) CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
MX390722B (en) DIURETIC RESISTANCE TREATMENT.
MX2009003532A (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin.